Suppr超能文献

颅内动脉瘤血流导向装置:DIVERSION 全国前瞻性队列研究。

Flow Diverters for Intracranial Aneurysms: The DIVERSION National Prospective Cohort Study.

机构信息

From the Department of Diagnostic and Therapeutic Neuroradiology, INSERM U1254, University Hospital of Nancy, France (B.G., R.A.).

Department of Neuroradiology, CHU de Bordeaux, France (J.B.).

出版信息

Stroke. 2019 Dec;50(12):3471-3480. doi: 10.1161/STROKEAHA.119.024722. Epub 2019 Oct 7.

Abstract

Background and Purpose- Flow diverters are used for endovascular therapy of intracranial aneurysms. We did a nationwide prospective study to investigate the safety and effectiveness of flow diversion at 12 months. Methods- DIVERSION was a national prospective cohort study including all flow diverters placement between October 2012 and February 2014 in France. The primary end point was the event-free survival rate at 12 months, defined as the occurrence of morbidity (intracranial hemorrhage, ischemic stroke, noncerebral hemorrhage, or neurological deficit due to mass effect), retreatment, or death within 12 months post-treatment. A quality control was carried out on 100% of the collected data and of at least 10% of the included patients in each center, chosen at random. All reported serious events were adjudicated by an independent Data Safety and Monitoring Board. Satisfactory occlusion was defined as 3 or 4 on Kamran scale by an independent imaging core laboratory at 12 months. Results- We enrolled 398 patients harboring 477 intracranial aneurysms. At least 1 morbidity-mortality event was noted in 95 of 408 interventions representing an event-free survival rate of 75.7% (95% CI, 71.1-79.7). The rate of permanent-related serious events and mortality was 5.9% and 1.2% at 12 months, respectively. Multivariate analysis showed that high baseline blood pressure (hazard ratio, 2.54; 95% CI, 1.35-4.79; =0.039), diabetes mellitus (hazard ratio, 3.70; 95% CI, 1.60-8.6; =0.0022), and larger aneurysms (hazard ratio, 1.07; 95% CI, 1.04-1.11; <0.0001) were associated with the occurrence of a neurological deficit. The satisfactory occlusion rate at 12 months was 79.9%, and the absence of high baseline blood pressure (odds ratio, 2.01; 95% CI, 1.12-3.71; =0.0193) and postprocedural satisfactory occlusion (odds ratio, 2.75; 95% CI, 1.49-5.09; =0.0012) were associated with a 12-month satisfactory occlusion. Conclusions- A satisfactory occlusion was achieved in almost 80% of cases after flow diverter treatment with a permanent-related serious event and mortality rates of 5.9% and 1.2% at 12 months, respectively.

摘要

背景与目的-血流导向装置用于颅内动脉瘤的血管内治疗。我们进行了一项全国性前瞻性研究,以调查 12 个月时血流导向装置的安全性和有效性。方法-DIVERSION 是一项全国性前瞻性队列研究,纳入了 2012 年 10 月至 2014 年 2 月期间在法国进行的所有血流导向装置放置。主要终点是 12 个月时无事件生存率,定义为治疗后 12 个月内发生发病率(颅内出血、缺血性卒中和非脑出血、或因肿块效应引起的神经功能缺损)、再治疗或死亡。对 100%收集的数据和每个中心至少 10%的纳入患者进行了质量控制,这些患者是随机选择的。所有报告的严重事件均由独立的数据安全和监测委员会进行裁决。12 个月时,通过独立的成像核心实验室,以 Kamran 量表 3 或 4 级定义为满意的闭塞。结果-我们纳入了 398 例 477 个颅内动脉瘤患者。在 408 例干预措施中,至少有 1 例出现了发病率-死亡率事件,无事件生存率为 75.7%(95%CI,71.1-79.7)。12 个月时永久性相关严重事件和死亡率分别为 5.9%和 1.2%。多变量分析显示,基线血压较高(风险比,2.54;95%CI,1.35-4.79;=0.039)、糖尿病(风险比,3.70;95%CI,1.60-8.6;=0.0022)和较大的动脉瘤(风险比,1.07;95%CI,1.04-1.11;<0.0001)与神经功能缺损的发生有关。12 个月时的满意闭塞率为 79.9%,而基线血压较高(比值比,2.01;95%CI,1.12-3.71;=0.0193)和术后满意闭塞(比值比,2.75;95%CI,1.49-5.09;=0.0012)与 12 个月时的满意闭塞有关。结论-血流导向装置治疗后,近 80%的病例达到满意的闭塞,12 个月时永久性相关严重事件和死亡率分别为 5.9%和 1.2%。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验